These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8254628)

  • 1. Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists.
    Sawyer JS; Baldwin RF; Sofia MJ; Floreancig P; Marder P; Saussy DL; Froelich LL; Silbaugh SA; Stengel PW; Cockerham SL
    J Med Chem; 1993 Nov; 36(24):3982-4. PubMed ID: 8254628
    [No Abstract]   [Full Text] [Related]  

  • 2. o-phenylphenols: potent and orally active leukotriene B4 receptor antagonists.
    Sofia MJ; Floreancig P; Bach NJ; Baker SR; Cockerham SL; Fleisch JH; Froelich LL; Jackson WT; Marder P; Roman CR
    J Med Chem; 1993 Nov; 36(24):3978-81. PubMed ID: 7902871
    [No Abstract]   [Full Text] [Related]  

  • 3. The discovery of LY293111, a novel, potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class.
    Sofia MJ; Floreancig P; Bach N; Baker SR; Nelson K; Sawyer JS; Baldwin R; Cockerham SL; Fleisch JH; Froelich LL; Jackson WT; Marder P; Roman CR; Saussy DL; Silbaugh SA; Spaethe SM; Stengel PW
    Adv Exp Med Biol; 1997; 400A():381-6. PubMed ID: 9547580
    [No Abstract]   [Full Text] [Related]  

  • 4. Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.
    Sawyer JS; Bach NJ; Baker SR; Baldwin RF; Borromeo PS; Cockerham SL; Fleisch JH; Floreancig P; Froelich LL; Jackson WT
    J Med Chem; 1995 Oct; 38(22):4411-32. PubMed ID: 7473568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and pharmacological evaluation of potent xanthone dicarboxylic acid leukotriene B4 receptor antagonists.
    Jackson WT; Boyd RJ; Froelich LL; Gapinski DM; Mallett BE; Sawyer JS
    J Med Chem; 1993 Jun; 36(12):1726-34. PubMed ID: 8389876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships study of two series of leukotriene B4 antagonists: novel indolyl and naphthyl compounds substituted with a 2-[methyl(2-phenethyl)amino]-2-oxoethyl side chain.
    Chan WK; Huang FC; Morrissette MM; Warus JD; Moriarty KJ; Galemmo RA; Dankulich WD; Poli G; Sutherland CA
    J Med Chem; 1996 Sep; 39(19):3756-68. PubMed ID: 8809164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential fatty acids are antagonists of the leukotriene B4 receptor.
    Yagaloff KA; Franco L; Simko B; Burghardt B
    Prostaglandins Leukot Essent Fatty Acids; 1995 May; 52(5):293-7. PubMed ID: 7630916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
    Jackson WT; Froelich LL; Boyd RJ; Schrementi JP; Saussy DL; Schultz RM; Sawyer JS; Sofia MJ; Herron DK; Goodson T; Snyder DW; Pechous PA; Spaethe SM; Roman CR; Fleisch JH
    J Pharmacol Exp Ther; 1999 Jan; 288(1):286-94. PubMed ID: 9862783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of leukotriene B4 receptor antagonist, LY293111Na, on antigen-induced bronchial hyperresponsiveness and leukocyte infiltration in sensitized guinea pigs.
    Asanuma F; Kuwabara K; Arimura A; Furue Y; Fleisch JH; Hori Y
    Inflamm Res; 2001 Mar; 50(3):136-41. PubMed ID: 11339501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel series of [2-[methyl(2-phenethyl)amino]-2-oxoethyl] benzene-containing leukotriene B4 antagonists: initial structure-activity relationships.
    Huang FC; Chan WK; Moriarty KJ; Poli G; Morrissette MM; Galemmo RA; Warus JD; Dankulich WP; Sutherland CA
    J Med Chem; 1996 Sep; 39(19):3748-55. PubMed ID: 8809163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.
    Daines RA; Chambers PA; Foley JJ; Griswold DE; Kingsbury WD; Martin LD; Schmidt DB; Sham KK; Sarau HM
    J Med Chem; 1996 Sep; 39(19):3837-41. PubMed ID: 8809171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.
    Daines RA; Chambers PA; Pendrak I; Jakas DR; Sarau HM; Foley JJ; Schmidt DB; Griswold DE; Martin LD; Tzimas MN
    J Med Chem; 1993 Sep; 36(18):2703-5. PubMed ID: 8410983
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel compounds that interact with both leukotriene B4 receptors and vanilloid TRPV1 receptors.
    McHugh D; McMaster RS; Pertwee RG; Roy S; Mahadevan A; Razdan RK; Ross RA
    J Pharmacol Exp Ther; 2006 Feb; 316(2):955-65. PubMed ID: 16207832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. trans-3-Benzyl-4-hydroxy-7-chromanylbenzoic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor.
    Reiter LA; Koch K; Piscopio AD; Showell HJ; Alpert R; Biggers MS; Chambers RJ; Conklyn MJ; Cooper K; Cortina SR; Dibrino JN; Dominy BW; Farrell CA; Hingorani GP; Martinelli GJ; Ramchandani M; Wright KF
    Bioorg Med Chem Lett; 1998 Jul; 8(14):1781-6. PubMed ID: 9873433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trisubstituted benzene leukotriene B4 receptor antagonists: synthesis and structure-activity relationships.
    Konno M; Nakae T; Sakuyama S; Odagaki Y; Nakai H; Hamanaka N
    Bioorg Med Chem; 1997 Aug; 5(8):1649-74. PubMed ID: 9313868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LTB4 receptor antagonists exacerbate T lymphocyte-mediated delayed hypersensitivity in guinea pigs.
    Wong PY; Lin KT; Godfrey HP
    Adv Exp Med Biol; 1997; 400A():247-51. PubMed ID: 9547565
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of leukotriene B4 as an inflammatory mediator in skin and the functional characterisation of LTB4 receptor antagonists.
    Ekerdt R; Buchmann B; Fröhlich W; Giesen C; Heindl J; Skuballa W
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():565-8. PubMed ID: 1847567
    [No Abstract]   [Full Text] [Related]  

  • 18. Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships.
    Daines RA; Chambers PA; Pendrak I; Jakas DR; Sarau HM; Foley JJ; Schmidt DB; Kingsbury WD
    J Med Chem; 1993 Oct; 36(22):3321-32. PubMed ID: 8230122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukotriene B4 costimulates 5-lipoxygenase activity in neutrophils via increased 5-lipoxygenase translocation.
    Serio KJ; Baker JR; Ring WL; Riddick CA; Bigby TD
    Am J Physiol; 1997 Apr; 272(4 Pt 1):C1329-34. PubMed ID: 9142859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biochemical/pharmacological profile of the novel leukotriene B4 receptor antagonist sodium (1S*, 3S*)-1-hydroxy-3-[(3 R*S*,E)-3-hydroxy-7-phenyl-1-hepten-1-yl]-1-cyclohexane acetate.
    Hullot P; Poudrel JM; Muller A; Escale R; Rossi JC; Girard JP; Bonne C
    Arzneimittelforschung; 1997 Jan; 47(1):51-8. PubMed ID: 9037445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.